The progress made in this area is particularly important for SSc-PAH, which often shows minimal and vague early symptoms, and among the currently used screening tools, like TTE, DLCO, and NT-proBNP, they are all limited by the fact that they lack specific standalone sensitivity and specificity. This evidence concerns the gene NPPB and systemic sclerosis.